"We believe OPKO shares continue to be significantly undervalued, and our strong cash position provides the ability to return capital to shareholders while adequately funding our pharmaceutical programs." — CEO
"Our stated objective... remains to reach profitability within this year." — 总裁（指BioReference不含肿瘤业务）
"Once the oncology transaction is closed... the remaining BioReference will be cash flow positive and profitable as measured before nonrecurring and noncash items." — CFO
"We intend to continue to reduce our remaining convertible debt and... plan to continue to reduce the number of shares outstanding in the most capital efficient way possible." — CFO
Prepared Metrics
Metric
Value
Speaker/Context
BioReference 2024年核心收入（不含肿瘤）
~$320M
CEO, 总裁
诊断板块Q1收入
$102.8M
CFO
4Kscore Q1同比增长
+14.5%
总裁
Q1裁员人数
136人（7%）
总裁
Q1年化成本节省
~$19M
总裁
医药板块Q1收入
$47.1M
CFO
Rayaldee Q1收入
$6.3M
CFO
Pfizer利润分成Q1
$4.5M
CFO
Q1合并净亏损
$67.6M ($0.10/股)
CFO
Q1末现金余额
~$450M
CFO
可转债交换减少债务
$159.2M
CFO
新增股票回购授权
$100M（总额$200M）
CEO, CFO
剩余回购额度
~$159M（超1.13亿股）
CFO
Q&A Batch (1-5 of 7)
Q1 — Maury Raycroft
Topic: NGENLA prescription dynamics and Pfizer’s EU application withdrawal
Key points:
Prescription growth rates for both NGENLA and GENOTROPIN continue; negative dynamics attributed to commercial environment, not competition or access.
Pfizer withdrew EU adult-setting application to focus on pediatric indications due to larger market size.
Company expects Q1 weakness to be a “first quarter only event,” leading to only a slight guidance reduction.
Mgmt stance: Neutral – acknowledges temporary headwinds but expects normalization; no direct Pfizer update provided.
Q2 — Yi Chen
Topic: GLP-1/glucagon tablet candidate development timeline and differentiation
Key points:
IND expected by end of 2025 or early 2026; Phase 1 results possible by end of 2026.
EBV trial: 200 healthy volunteers, multiple cohorts with different adjuvants; Phase 1 focuses on tolerability/safety, not efficacy; immunogenicity biomarkers will provide indirect efficacy signals.
TCE candidate (2001): Phase 1 has 6 dose levels; currently in 4th level, progressing to 5th and 6th; completion expected by end of 2025.
After Phase 1, will enter efficacy part as basket trial in solid cancers, then narrow to 1–2 most promising cancers in Phase 1b.
Mgmt stance: Neutral – no efficacy data yet; timeline and design outlined without overpromising.
Q5 — Edward Tenthoff
Topic: Subcu obesity/NASH program and oral development plan
Key points:
Both subcu and oral programs in pre-IND phase; GMP material being manufactured; FDA interactions ongoing for trial design.
Phase 1a/b will focus on safety, PK/PD, and pharmacological behavior before advancing to Phase 2a/2b.
No specific timing for study start provided beyond “working diligently to enter Phase I.”
Mgmt stance: Neutral – early-stage development; no concrete milestones or differentiation strategy detailed beyond safety-focused Phase 1.
Q&A Batch (6-7 of 7)
Q6 — Yale Jen
Topic: Tariff impact on supply chain and MESH product development target
Key points:
Tariffs: BioReference buys most products in the U.S., some manufactured internationally; company sees it as a “manageable risk” and is monitoring alternatives.
Pharmaceutical imports: Rayaldee and Pfizer’s NGENLA/GENOTROPIN are made in Ireland; cost of goods is a “minor component” of total cost structure, so no significant impact expected.
R&D: Relies on European and Chinese CROs/CDMOs for a “minor amount” of services; no significant impact from tariffs seen.
MESH development: Inclined to target F3 NASH or F4 pre-cirrhotic NASH (later stage), not F2/early F3 due to existing alternatives; decision not yet finalized.
Mgmt stance: Neutral – tariffs viewed as manageable with minimal financial impact; MESH targeting is still under consideration.
BARDA revenue guidance revised down to $38M–$44M from prior $40M–$48M.
NGENLA: Q1 2025 was a low quarter; script data shows “growing franchise” with no significant changes; company expects this to be a “nonrecurring issue” and rebound to historical norms; no recent conversation with Pfizer since results.
Diagnostics business: Even without selling oncology assets, company had plans to exit certain testing lines and clients to achieve cash flow breakeven this year; management states they “fully expected to get there and certainly could.”
Mgmt stance: Neutral on BARDA (guidance lowered); bullish on NGENLA (one-quarter issue, script data positive); bullish on diagnostics (breakeven achievable without asset sale).